Advanced
  Home Compare Reports

Comparison with Similar Reports

Needle-Free Injection System Market by Technology (Jet, Spring, Micro-array Patch), by Product (Prefilled, Fillable), Type of Medication (Liquid, Powd...

Publisher:        MarketsandMarkets

# of Pages:        232

Rating: 

1 User License $4,950

Publication Date:  February, 2022

Price:       $4,950 / User License




1 INTRODUCTION 29
1.1 OBJECTIVES OF THE STUDY 29
1.2 MARKET DEFINITION 29
1.2.1 INCLUSIONS AND EXCLUSIONS 30
1.3 MARKET SCOPE 31
1.3.1 MARKETS COVERED 31
1.3.2 MARKETS COVERED–BY REGION 31
1.3.3 YEARS CONSIDERED FOR THE STUDY 32
1.4 CURRENCY 32
TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD 32
1.5 STAKEHOLDERS 33
1.6 SUMMARY OF CHANGES 33
2 RESEARCH METHODOLOGY 35
2.1 RESEARCH APPROACH 35
FIGURE 1 RESEARCH DESIGN 35
2.1.1 SECONDARY DATA 36
2.1.1.1 Key data from secondary sources 37
2.1.2 PRIMARY DATA 37
2.1.2.1 Primary sources 37
2.1.2.2 Key data from primary sources 38
2.1.2.3 Breakdown of primaries 39
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION 39
2.2 MARKET SIZE ESTIMATION 39
FIGURE 3 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS (2020) 40
FIGURE 4 SUPPLY SIDE ANALYSIS: NEEDLE-FREE INJECTION SYSTEM MARKET 41
FIGURE 5 TOP-DOWN APPROACH 42
FIGURE 6 CAGR PROJECTIONS FROM THE ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NEEDLE-FREE INJECTION SYSTEM MARKET (2021– 2026) 43
FIGURE 7 CAGR PROJECTIONS: SUPPLY SIDE ANALYSIS OF THE NEEDLE-FREE INJECTION SYSTEM MARKET (2020) 44
2.3 MARKET BREAKDOWN & DATA TRIANGULATION 45
FIGURE 8 DATA TRIANGULATION METHODOLOGY 45
2.4 KEY INDUSTRY INSIGHTS 46
2.5 LIMITATIONS 46
2.5.1 METHODOLOGY-RELATED LIMITATIONS 46
2.6 RISK ASSESSMENT 47
2.7 ASSUMPTIONS FOR THE STUDY 47
3 EXECUTIVE SUMMARY 48
FIGURE 9 NEEDLE-FREE INJECTION SYSTEM MARKET, BY PRODUCT,
2021 VS. 2026 (USD MILLION) 48
FIGURE 10 NEEDLE-FREE INJECTION SYSTEM MARKET, BY TECHNOLOGY,
2021 VS. 2026 (USD MILLION) 49
FIGURE 11 NEEDLE-FREE INJECTION SYSTEM MARKET, BY TYPE,
2021 VS. 2026 (USD MILLION) 50
FIGURE 12 NEEDLE-FREE INJECTION SYSTEM MARKET, BY SITE OF DELIVERY,
2021 VS. 2026 (USD MILLION) 50
FIGURE 13 NEEDLE-FREE INJECTION SYSTEM MARKET, BY APPLICATION,
2021 VS. 2026 (USD MILLION) 51
FIGURE 14 NEEDLE-FREE INJECTION SYSTEM MARKET, BY END USER,
2021 VS. 2026 (USD MILLION) 52
FIGURE 15 GEOGRAPHICAL SNAPSHOT OF THE NEEDLE-FREE INJECTION
SYSTEM MARKET 53
4 PREMIUM INSIGHTS 54
4.1 NEEDLE-FREE INJECTION SYSTEM MARKET OVERVIEW 54
FIGURE 16 HIGH PREVALENCE OF INFECTIOUS DISEASES, GROWING INCIDENCE OF COMMUNICABLE DISEASES DUE TO NEEDLESTICK INJURIES, AND RISE IN DEMAND FOR SELF-INJECTION DEVICES TO DRIVE MARKET GROWTH 54
4.2 ASIA PACIFIC NEEDLE-FREE INJECTION SYSTEM MARKET,
BY APPLICATION AND COUNTRY 55
FIGURE 17 VACCINATION ACCOUNTED FOR THE LARGEST SHARE IN ASIA PACIFIC 55
4.3 NEEDLE-FREE INJECTION SYSTEM MARKET: GEOGRAPHICAL GROWTH OPPORTUNITIES 56
FIGURE 18 CHINA TO REGISTER HIGHEST GROWTH RATES DURING
THE FORECAST PERIOD 56
4.4 NEEDLE-FREE INJECTION SYSTEM MARKET: DEVELOPING VS DEVELOPED COUNTRIES 57
FIGURE 19 DEVELOPING COUNTRIES TO OFFER HIGHER GROWTH 57
4.5 REGIONAL MIX: NEEDLE-FREE INJECTION SYSTEM MARKET 57
FIGURE 20 APAC TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD 57
5 MARKET OVERVIEW 58
5.1 INTRODUCTION 58
5.2 MARKET DYNAMICS: IMPACT ANALYSIS 58
5.2.1 DRIVERS 59
5.2.1.1 High prevalence of infectious diseases globally 59
FIGURE 21 PREVALENCE OF INFECTIOUS DISEASES WORLDWIDE 60
TABLE 2 PREVALENCE OF HIV WORLDWIDE (2017 VS. 2020) 61
5.2.1.2 Increasing incidence of communicable diseases due to needlestick injuries 62
5.2.1.3 Rise in demand for self-injection devices 62
5.2.1.4 Increased number of technological advancements 62
5.2.1.5 Reduction in injection system costs 63
 
5.2.2 RESTRAINTS 63
5.2.2.1 Higher cost of development as compared to conventional injection systems 63
5.2.2.2 Limitation with large volume and intravenous administration systems 64
5.2.3 OPPORTUNITIES 64
5.2.3.1 Rising demand for biosimilars and vaccination processes 64
5.2.3.2 Increasing number of emerging markets 64
5.2.4 CHALLENGES 65
5.2.4.1 Rise in need to ensure system sterility 65
5.2.4.2 Growth in alternative modes of drug delivery 65
5.3 ASSESSMENT OF IMPACT OF COVID-19 ON ECONOMIC SCENARIO IN NEEDLE-FREE INJECTION SYSTEM MARKET 66
FIGURE 22 IMPACT OF COVID-19 PANDEMIC ON ENTIRE NEEDLE-FREE INJECTION ECOSYSTEM (2020)- KEY HOT SPOTS OF ACTIVITY ARE HIGHLIGHTED PREVALENCE OF INFECTIOUS DISEASES WORLDWIDE 66
5.4 PRICING ANALYSIS 67
TABLE 3 AVERAGE SELLING PRICE OF NEEDLE-FREE INJECTORS IN NORTH AMERICA, BY APPLICATIONS, FOR 2020 67
5.5 SUPPLY CHAIN ANALYSIS 67
FIGURE 23 SUPPLY CHAIN ANALYSIS: NEEDLE-FREE INJECTION SYSTEM MARKET (2020) 68
5.6 PATENT ANALYSIS 69
5.6.1 PATENT PUBLICATION TRENDS FOR NEEDLE-FREE INJECTION
SYSTEM MARKET 69
FIGURE 24 GLOBAL PATENT PUBLICATION TRENDS IN NEEDLE-FREE INJECTION SYSTEM, 2016–2021 70
5.6.2 TOP APPLICANTS (COMPANIES) OF NEEDLE-FREE INJECTION SYSTEM PATENTS 70
FIGURE 25 TOP COMPANIES THAT APPLIED FOR NEEDLE-FREE INJECTION SYSTEM PATENTS, 2016–2021 70
5.6.3 JURISDICTION ANALYSIS: TOP APPLICANTS (COUNTRIES) FOR PATENTS IN NEEDLE-FREE INJECTION SYSTEM MARKET 71
FIGURE 26 JURISDICTION ANALYSIS: TOP APPLICANT COUNTRIES FOR NEEDLE-FREE INJECTION SYSTEM PATENTS, 2016–2021 71
5.7 VALUE CHAIN ANALYSIS 71
FIGURE 27 NEEDLE-FREE INJECTION SYSTEM MARKET: VALUE CHAIN ANALYSIS (2020) 72
5.8 TECHNOLOGY ANALYSIS 72
5.8.1 KEY TECHNOLOGY: JET-BASED NEEDLE-FREE INJECTORS 72
5.8.2 ADJACENT TECHNOLOGY: SPRING-BASED NEEDLE-FREE INJECTORS 72
5.8.3 MICROARRAY PATCH 72
5.8.4 OTHER TECHNOLOGIES 73
5.9 REGULATORY LANDSCAPE 73
TABLE 4 REGULATORY STANDARDS/APPROVALS REQUIRED FOR NEEDLE-FREE INJECTION PRODUCTS, BY COUNTRY/REGION 73
 
5.10 PORTER’S FIVE FORCES ANALYSIS 73
TABLE 5 NEEDLE-FREE INJECTION SYSTEM: PORTER’S FIVE FORCES ANALYSIS 73
5.10.1 THREAT FROM NEW ENTRANTS 74
5.10.2 COMPETITIVE RIVALRY 74
5.10.3 BARGAINING POWER OF BUYERS 75
5.10.4 BARGAINING POWER OF SUPPLIERS 75
5.10.5 THREAT FROM SUBSTITUTES 75
6 NEEDLE-FREE INJECTION SYSTEM MARKET, BY PRODUCT 76
6.1 INTRODUCTION 77
TABLE 6 NEEDLE-FREE INJECTION SYSTEM MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 77
6.2 FILLABLE NEEDLE-FREE INJECTORS 77
6.2.1 TREATMENT OF DISEASES THAT REQUIRE REGULAR ADMINISTRATION OF MEDICATION TO DRIVE MARKET GROWTH 77
TABLE 7 FILLABLE NEEDLE-FREE INJECTORS MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 78
6.3 PREFILLED NEEDLE-FREE INJECTORS 79
6.3.1 SELF-ADMINISTRATION OF DRUGS FOR TREATMENT TO DRIVE
MARKET GROWTH 79
TABLE 8 PREFILLED NEEDLE-FREE INJECTORS MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 79
7 NEEDLE-FREE INJECTION SYSTEM MARKET, BY TECHNOLOGY 80
7.1 INTRODUCTION 81
TABLE 9 NEEDLE-FREE INJECTION SYSTEM MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 81
7.2 JET-BASED NEEDLE-FREE INJECTORS 82
7.2.1 WIDE APPLICATIONS OF JET-BASED INJECTIONS
TO DRIVE SEGMENT GROWTH 82
TABLE 10 JET-BASED NEEDLE-FREE INJECTION SYSTEM MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 82
7.3 SPRING-BASED NEEDLE-FREE INJECTORS 83
7.3.1 LOW COST OF SPRING-BASED INJECTORS TO DRIVE MARKET GROWTH 83
TABLE 11 SPRING-BASED NEEDLE-FREE INJECTION SYSTEM MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 83
7.4 MICRO-ARRAY PATCH 84
7.4.1 FUTURE DEMAND FOR VACCINES AND CONTRACEPTIVES MICRO-ARRAY PATCHES TO DRIVE MARKET GROWTH 84
TABLE 12 MICRO-ARRAY PATCH MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 84
7.5 OTHER TECHNOLOGIES 85
TABLE 13 OTHER TECHNOLOGIES NEEDLE-FREE INJECTION SYSTEM MARKET,
BY COUNTRY, 2019–2026 (USD MILLION) 85
 
8 NEEDLE-FREE INJECTION SYSTEM MARKET, BY TYPE 86
8.1 INTRODUCTION 87
TABLE 14 NEEDLE-FREE INJECTION SYSTEM MARKET, BY TYPE,
2019–2026 (USD MILLION) 87
8.2 LIQUID-BASED NEEDLE-FREE INJECTORS 87
8.2.1 INCREASE IN VACCINATION FOR INFECTIOUS DISEASES TO DRIVE MARKET GROWTH 87
TABLE 15 LIQUID-BASED NEEDLE-FREE INJECTION SYSTEM MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 88
8.3 POWDER-BASED NEEDLE-FREE INJECTORS 89
8.3.1 REQUIREMENT OF STABLE DRUGS TO DRIVE MARKET GROWTH 89
TABLE 16 POWDER-BASED NEEDLE FREE INJECTION SYSTEM MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 89
8.4 PROJECTILE/DEPOT-BASED NEEDLE-FREE INJECTORS 90
8.4.1 USE OF INERT MATERIAL OR SELF MEDICAMENT TO DRIVE MARKET GROWTH 90
TABLE 17 PROJECTILE/DEPOT-BASED NEEDLE FREE INJECTION SYSTEM MARKET,
BY COUNTRY, 2019–2026 (USD MILLION) 90
9 NEEDLE-FREE INJECTION SYSTEM MARKET, BY SITE OF DELIVERY 91
9.1 INTRODUCTION 92
TABLE 18 NEEDLE-FREE INJECTION SYSTEM MARKET, BY SITE OF DELIVERY,
2019–2026 (USD MILLION) 92
9.2 SUBCUTANEOUS NEEDLE-FREE INJECTORS 92
9.2.1 PREFERENCE FOR ADMINISTERING DELICATE DRUGS FOR INFECTIOUS DISEASES TO DRIVE MARKET GROWTH 92
TABLE 19 SUBCUTANEOUS NEEDLE-FREE INJECTION SYSTEM MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 93
9.2.2 INTRAMUSCULAR NEEDLE-FREE INJECTORS 93
9.2.2.1 Increase in vaccination requirement to drive market growth 93
TABLE 20 INTRAMUSCULAR NEEDLE-FREE INJECTION SYSTEM MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 94
9.2.3 INTRADERMAL NEEDLE-FREE INJECTORS 94
9.2.3.1 Use of inert material or self medicament to drive market growth 94
TABLE 21 INTRADERMAL NEEDLE-FREE INJECTION SYSTEM MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 95
10 NEEDLE-FREE INJECTION SYSTEM MARKET, BY APPLICATION 96
10.1 INTRODUCTION 97
TABLE 22 NEEDLE-FREE INJECTION SYSTEM MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 97
10.2 VACCINE DELIVERY 97
10.2.1 COST-EFFECTIVENESS AND RISE OF PREVENTIVE MEASURES TO DRIVE GROWTH IN VACCINES DELIVERY 97
TABLE 23 NEEDLE-FREE INJECTION SYSTEM MARKET FOR VACCINE DELIVERY,
BY COUNTRY, 2019–2026 (USD MILLION) 98
 
10.3 INSULIN DELIVERY 98
10.3.1 RISING INCIDENCE OF DIABETES TO DRIVE MARKET GROWTH 98
TABLE 24 NEEDLE-FREE INJECTION SYSTEM MARKET FOR INSULIN DELIVERY,
BY COUNTRY, 2019–2026 (USD MILLION) 99
10.4 ONCOLOGY 100
10.4.1 RISE IN CANCER PREVALENCE AND AVAILABILITY OF CANCER TREATMENT TO DRIVE MARKET GROWTH 100
TABLE 25 NEEDLE-FREE INJECTION SYSTEM MARKET FOR ONCOLOGY, BY COUNTRY, 2019–2026 (USD MILLION) 100
10.5 PAIN MANAGEMENT 101
10.5.1 INCREASED PREVALENCE AND TREATMENT OF CHRONIC DISEASES TO DRIVE MARKET GROWTH 101
TABLE 26 NEEDLE-FREE INJECTION SYSTEM MARKET FOR PAIN MANAGEMENT,
BY COUNTRY, 2019–2026 (USD MILLION) 101
10.6 DERMATOLOGY 102
10.6.1 INCREASED DERMATOLOGY-BASED TREATMENTS AND SURGERIES TO DRIVE MARKET GROWTH 102
TABLE 27 NEEDLE-FREE INJECTION SYSTEM MARKET FOR DERMATOLOGY,
BY COUNTRY, 2019–2026 (USD MILLION) 102
10.7 OTHER APPLICATIONS 103
TABLE 28 NEEDLE-FREE INJECTION SYSTEM MARKET FOR OTHER APPLICATIONS,
BY COUNTRY, 2019–2026 (USD MILLION) 103
11 NEEDLE-FREE INJECTION SYSTEM MARKET, BY END USER 104
11.1 INTRODUCTION 105
TABLE 29 NEEDLE-FREE INJECTION SYSTEM MARKET, BY END USER,
2019–2026 (USD MILLION) 105
11.2 HOSPITALS & CLINICS 106
11.2.1 INCREASING USE OF NEEDLE-LESS VACCINATION TO DRIVE ADOPTION 106
TABLE 30 NEEDLE-FREE INJECTION SYSTEM MARKET FOR HOSPITALS & CLINICS,
BY COUNTRY, 2019–2026 (USD MILLION) 106
11.3 HOMECARE SETTINGS 107
11.3.1 GROWING NEED FOR HOME SELF-ADMINISTRATION AND RISING GERIATRIC POPULATION TO DRIVE MARKET GROWTH 107
TABLE 31 NEEDLE-FREE INJECTION SYSTEM MARKET FOR HOMECARE SETTINGS,
BY COUNTRY, 2019–2026 (USD MILLION) 107
11.4 RESEARCH LABORATORIES 108
11.4.1 GROWING RESEARCH OF DRUG TESTING ON ANIMALS TO DRIVE MARKET GROWTH 108
TABLE 32 NEEDLE-FREE INJECTION SYSTEM MARKET FOR RESEARCH LABORATORIES, BY COUNTRY, 2019–2026 (USD MILLION) 108
11.5 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 109
11.5.1 INCREASING FOCUS ON BIOLOGICS DELIVERY RESEARCH TO DRIVE USAGE 109
TABLE 33 NEEDLE-FREE INJECTION SYSTEM MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION) 109
 
11.6 OTHER END USERS 110
TABLE 34 NEEDLE-FREE INJECTION SYSTEM MARKET FOR OTHER END USERS,
BY COUNTRY, 2019–2026 (USD MILLION) 110
12 NEEDLE-FREE INJECTION SYSTEM MARKET, BY REGION 111
12.1 INTRODUCTION 112
FIGURE 28 US TO DOMINATE NEEDLE-FREE INJECTION SYSTEM MARKET DURING FORECAST PERIOD 112
TABLE 35 NEEDLE-FREE INJECTION SYSTEM MARKET, BY REGION,
2019–2026 (USD MILLION) 113
12.2 NORTH AMERICA 113
FIGURE 29 NORTH AMERICA: NEEDLE-FREE INJECTION SYSTEM MARKET SNAPSHOT 114
TABLE 36 NORTH AMERICA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 115
TABLE 37 NORTH AMERICA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY PRODUCT, 2019–2026 (USD MILLION) 115
TABLE 38 NORTH AMERICA: NEEDLE-FREE INJECTION SYSTEM MARKET,
BY TECHNOLOGY, 2019–2026 (USD MILLION) 115
TABLE 39 NORTH AMERICA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TYPE, 2019–2026 (USD MILLION) 116
TABLE 40 NORTH AMERICA: NEEDLE-FREE INJECTION SYSTEM MARKET,
BY SITE OF DELIVERY, 2019–2026 (USD MILLION) 116
TABLE 41 NORTH AMERICA: NEEDLE-FREE INJECTION SYSTEM MARKET,
BY APPLICATION, 2019–2026 (USD MILLION) 117
TABLE 42 NORTH AMERICA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY END USER, 2019–2026 (USD MILLION) 117
12.2.1 US 118
12.2.1.1 US to account for the largest share of needle-free injection system market 118
TABLE 43 US: MACROECONOMIC INDICATORS 118
TABLE 44 US: NEEDLE-FREE INJECTION SYSTEM MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 119
TABLE 45 US: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 119
TABLE 46 US: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TYPE,
2019–2026 (USD MILLION) 119
TABLE 47 US: NEEDLE-FREE INJECTION SYSTEM MARKET, BY SITE OF DELIVERY,
2019–2026 (USD MILLION) 120
TABLE 48 US: NEEDLE-FREE INJECTION SYSTEM MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 120
TABLE 49 US: NEEDLE-FREE INJECTION SYSTEM MARKET, BY END USER,
2019–2026 (USD MILLION) 121
12.2.2 CANADA 121
12.2.2.1 Availability of research funding and implementation of favorable government initiatives to drive market growth 121
TABLE 50 CANADA: MACROECONOMIC INDICATORS 122
TABLE 51 CANADA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 122
TABLE 52 CANADA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 123
TABLE 53 CANADA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TYPE,
2019–2026 (USD MILLION) 123
TABLE 54 CANADA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY SITE OF DELIVERY, 2019–2026 (USD MILLION) 124
TABLE 55 CANADA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 124
TABLE 56 CANADA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY END USER,
2019–2026 (USD MILLION) 125
12.3 EUROPE 125
FIGURE 30 EUROPE: NEEDLE-FREE INJECTION SYSTEM MARKET SNAPSHOT 126
TABLE 57 EUROPE: NEEDLE-FREE INJECTION SYSTEM MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 127
TABLE 58 EUROPE: NEEDLE-FREE INJECTION SYSTEM MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 127
TABLE 59 EUROPE: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 128
TABLE 60 EUROPE: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TYPE,
2019–2026 (USD MILLION) 128
TABLE 61 EUROPE: NEEDLE-FREE INJECTION SYSTEM MARKET, BY SITE OF DELIVERY, 2019–2026 (USD MILLION) 129
TABLE 62 EUROPE: NEEDLE-FREE INJECTION SYSTEM MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 129
TABLE 63 EUROPE: NEEDLE-FREE INJECTION SYSTEM MARKET, BY END USER,
2019–2026 (USD MILLION) 130
12.3.1 GERMANY 130
12.3.1.1 Increasing demand for self-injection devices to drive market demand 130
TABLE 64 GERMANY: MACROECONOMIC INDICATORS 131
TABLE 65 GERMANY: NEEDLE-FREE INJECTION SYSTEM MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 131
TABLE 66 GERMANY: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 132
TABLE 67 GERMANY: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TYPE,
2019–2026 (USD MILLION) 132
TABLE 68 GERMANY: NEEDLE-FREE INJECTION SYSTEM MARKET, BY SITE OF DELIVERY, 2019–2026 (USD MILLION) 133
TABLE 69 GERMANY: NEEDLE-FREE INJECTION SYSTEM MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 133
TABLE 70 GERMANY: NEEDLE-FREE INJECTION SYSTEM MARKET, BY END USER,
2019–2026 (USD MILLION) 134
12.3.2 FRANCE 134
12.3.2.1 High prevalence of age-related chronic diseases and infectious diseases to drive market growth 134
TABLE 71 FRANCE: MACROECONOMIC INDICATORS 135
TABLE 72 FRANCE: NEEDLE-FREE INJECTION SYSTEM MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 135
TABLE 73 FRANCE: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 136
TABLE 74 FRANCE: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TYPE,
2019–2026 (USD MILLION) 136
TABLE 75 FRANCE: NEEDLE-FREE INJECTION SYSTEM MARKET, BY SITE OF DELIVERY, 2019–2026 (USD MILLION) 137
TABLE 76 FRANCE: NEEDLE-FREE INJECTION SYSTEM MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 137
TABLE 77 FRANCE: NEEDLE-FREE INJECTION SYSTEM MARKET, BY END USER,
2019–2026 (USD MILLION) 138
12.3.3 UK 138
12.3.3.1 Increasing incidence of chronic diseases and rising prevalence of obesity to drive market growth 138
TABLE 78 UK: MACROECONOMIC INDICATORS 139
TABLE 79 UK: NEEDLE-FREE INJECTION SYSTEM MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 139
TABLE 80 UK: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 140
TABLE 81 UK: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TYPE,
2019–2026 (USD MILLION) 140
TABLE 82 UK: NEEDLE-FREE INJECTION SYSTEM MARKET, BY SITE OF DELIVERY,
2019–2026 (USD MILLION) 141
TABLE 83 UK: NEEDLE-FREE INJECTION SYSTEM MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 141
TABLE 84 UK: NEEDLE-FREE INJECTION SYSTEM MARKET, BY END USER,
2019–2026 (USD MILLION) 142
12.3.4 ITALY 142
12.3.4.1 Increasing geriatric population and prevalence of chronic diseases to drive market growth 142
TABLE 85 ITALY: MACROECONOMIC INDICATORS 143
TABLE 86 ITALY: NEEDLE-FREE INJECTION SYSTEM MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 143
TABLE 87 ITALY: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 144
TABLE 88 ITALY: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TYPE,
2019–2026 (USD MILLION) 144
TABLE 89 ITALY: NEEDLE-FREE INJECTION SYSTEM MARKET, BY SITE OF DELIVERY, 2019–2026 (USD MILLION) 145
TABLE 90 ITALY: NEEDLE-FREE INJECTION SYSTEM MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 145
TABLE 91 ITALY: NEEDLE-FREE INJECTION SYSTEM MARKET, BY END USER,
2019–2026 (USD MILLION) 146
12.3.5 SPAIN 146
12.3.5.1 Increasing prevalence of chronic diseases and technological advancement to drive market growth 146
TABLE 92 SPAIN: MACROECONOMIC INDICATORS 147
TABLE 93 SPAIN: NEEDLE-FREE INJECTION SYSTEM MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 147
TABLE 94 SPAIN: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 148
TABLE 95 SPAIN: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TYPE,
2019–2026 (USD MILLION) 148
TABLE 96 SPAIN: NEEDLE-FREE INJECTION SYSTEM MARKET, BY SITE OF DELIVERY, 2019–2026 (USD MILLION) 149
TABLE 97 SPAIN: NEEDLE-FREE INJECTION SYSTEM MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 149
TABLE 98 SPAIN: NEEDLE-FREE INJECTION SYSTEM MARKET, BY END USER,
2019–2026 (USD MILLION) 150
12.3.6 REST OF EUROPE 150
TABLE 99 ROE: NEEDLE-FREE INJECTION SYSTEM MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 150
TABLE 100 ROE: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 151
TABLE 101 ROE: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TYPE,
2019–2026 (USD MILLION) 151
TABLE 102 ROE: NEEDLE-FREE INJECTION SYSTEM MARKET, BY SITE OF DELIVERY, 2019–2026 (USD MILLION) 152
TABLE 103 ROE: NEEDLE-FREE INJECTION SYSTEM MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 152
TABLE 104 ROE: NEEDLE-FREE INJECTION SYSTEM MARKET, BY END USER,
2019–2026 (USD MILLION) 153
12.4 ASIA PACIFIC 153
FIGURE 31 ASIA PACIFIC: NEEDLE-FREE INJECTION SYSTEM MARKET SNAPSHOT 154
TABLE 105 APAC: NEEDLE-FREE INJECTION SYSTEM MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 155
TABLE 106 APAC: NEEDLE-FREE INJECTION SYSTEM MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 155
TABLE 107 APAC: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 155
TABLE 108 APAC: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TYPE,
2019–2026 (USD MILLION) 156
TABLE 109 APAC: NEEDLE-FREE INJECTION SYSTEM MARKET, BY SITE OF DELIVERY, 2019–2026 (USD MILLION) 156
TABLE 110 APAC: NEEDLE-FREE INJECTION SYSTEM MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 157
TABLE 111 APAC: NEEDLE-FREE INJECTION SYSTEM MARKET, BY END USER,
2019–2026 (USD MILLION) 157
12.4.1 JAPAN 158
12.4.1.1 Increasing geriatric population and higher adoption advance technology to drive market growth 158
TABLE 112 JAPAN: MACROECONOMIC INDICATORS 158
TABLE 113 JAPAN: NEEDLE-FREE INJECTION SYSTEM MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 158
TABLE 114 JAPAN: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 159
TABLE 115 JAPAN: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TYPE,
2019–2026 (USD MILLION) 159
TABLE 116 JAPAN: NEEDLE-FREE INJECTION SYSTEM MARKET, BY SITE OF DELIVERY, 2019–2026 (USD MILLION) 160
TABLE 117 JAPAN: NEEDLE-FREE INJECTION SYSTEM MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 160
TABLE 118 JAPAN: NEEDLE-FREE INJECTION SYSTEM MARKET, BY END USER,
2019–2026 (USD MILLION) 161
12.4.2 CHINA 161
12.4.2.1 Growing prevalence of lifestyle-related and chronic diseases to drive market growth 161
TABLE 119 CHINA: MACROECONOMIC INDICATORS 162
TABLE 120 CHINA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 162
TABLE 121 CHINA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 163
TABLE 122 CHINA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TYPE,
2019–2026 (USD MILLION) 163
TABLE 123 CHINA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY SITE OF DELIVERY, 2019–2026 (USD MILLION) 164
TABLE 124 CHINA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 164
TABLE 125 CHINA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY END USER,
2019–2026 (USD MILLION) 165
12.4.3 INDIA 165
12.4.3.1 Collaboration with key players in needle-free injections to drive market growth 165
TABLE 126 INDIA: MACROECONOMIC INDICATORS 166
TABLE 127 INDIA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 166
TABLE 128 INDIA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 167
TABLE 129 INDIA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TYPE,
2019–2026 (USD MILLION) 167
TABLE 130 INDIA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY SITE OF DELIVERY, 2019–2026 (USD MILLION) 168
TABLE 131 INDIA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 168
TABLE 132 INDIA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY END USER,
2019–2026 (USD MILLION) 169
12.4.4 REST OF ASIA PACIFIC 169
TABLE 133 ROAPAC: NEEDLE-FREE INJECTION SYSTEM MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 170
TABLE 134 ROAPAC: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 170
TABLE 135 ROAPAC: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TYPE,
2019–2026 (USD MILLION) 170
TABLE 136 ROAPAC: NEEDLE-FREE INJECTION SYSTEM MARKET, BY SITE OF DELIVERY, 2019–2026 (USD MILLION) 171
TABLE 137 ROAPAC: NEEDLE-FREE INJECTION SYSTEM MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 171
TABLE 138 ROAPAC: NEEDLE-FREE INJECTION SYSTEM MARKET, BY END USER,
2019–2026 (USD MILLION) 172
12.5 LATIN AMERICA 172
TABLE 139 LATIN AMERICA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY PRODUCT, 2019–2026 (USD MILLION) 172
TABLE 140 LATIN AMERICA: NEEDLE-FREE INJECTION SYSTEM MARKET,
BY TECHNOLOGY, 2019–2026 (USD MILLION) 173
TABLE 141 LATIN AMERICA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TYPE,
2019–2026 (USD MILLION) 173
TABLE 142 LATIN AMERICA: NEEDLE-FREE INJECTION SYSTEM MARKET,
BY SITE OF DELIVERY, 2019–2026 (USD MILLION) 174
TABLE 143 LATIN AMERICA: NEEDLE-FREE INJECTION SYSTEM MARKET,
BY APPLICATION, 2019–2026 (USD MILLION) 174
TABLE 144 LATIN AMERICA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY END USER, 2019–2026 (USD MILLION) 175
12.6 MIDDLE EAST & AFRICA 175
12.6.1 SIGNIFICANT SUPPORT FROM GOVERNMENTS AND GLOBAL FIRMS TO DRIVE MARKET GROWTH 175
TABLE 145 AFRICA: MACROECONOMIC INDICATORS 176
TABLE 146 MIDDLE EAST & AFRICA: NEEDLE-FREE INJECTION SYSTEM MARKET,
BY PRODUCT, 2019–2026 (USD MILLION) 176
TABLE 147 MIDDLE EAST & AFRICA: NEEDLE-FREE INJECTION SYSTEM MARKET,
BY TECHNOLOGY, 2019–2026 (USD MILLION) 177
TABLE 148 MIDDLE EAST & AFRICA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TYPE, 2019–2026 (USD MILLION) 177
TABLE 149 MIDDLE EAST & AFRICA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY SITE OF DELIVERY, 2019–2026 (USD MILLION) 178
TABLE 150 MIDDLE EAST & AFRICA: NEEDLE-FREE INJECTION SYSTEM MARKET,
BY APPLICATION, 2019–2026 (USD MILLION) 178
TABLE 151 MIDDLE EAST & AFRICA: NEEDLE-FREE INJECTION SYSTEM MARKET,
BY END USER, 2019–2026 (USD MILLION) 179
13 COMPETITIVE LANDSCAPE 180
13.1 OVERVIEW 180
13.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 180
13.3 REVENUE SHARE ANALYSIS FOR KEY PLAYERS IN THE NEEDLE-FREE INJECTION SYSTEM MARKET 181
13.4 NEEDLE-FREE INJECTION SYSTEM MARKET RANKING 181
13.5 COMPANY EVALUATION QUADRANT 183
FIGURE 32 NEEDLE-FREE INJECTION SYSTEM MARKET: COMPANY EVALUATION MATRIX, 2020 183
13.5.1 STARS 184
13.5.2 PERVASIVE PLAYERS 184
13.5.3 EMERGING LEADERS 184
13.5.4 PARTICIPANTS 184
13.6 COMPETITIVE LEADERSHIP MAPPING FOR SMES & START-UPS 185
FIGURE 33 NEEDLE-FREE INJECTION SYSTEM MARKET: COMPANY EVALUATION MATRIX FOR SMES & START-UP 185
13.6.1 PROGRESSIVE COMPANIES 186
13.6.2 DYNAMIC COMPANIES 186
13.6.3 STARTING BLOCKS 186
13.6.4 RESPONSIVE COMPANIES 186
13.7 COMPETITIVE BENCHMARKING 186
13.7.1 OVERALL COMPANY FOOTPRINT 186
TABLE 153 OVERALL COMPANY FOOTPRINT (25 COMPANIES) 186
TABLE 154 COMPANY FOOTPRINT: BY-PRODUCTS (25 COMPANIES) 188
TABLE 155 COMPANY FOOTPRINT: BY TECHNOLOGY (25 COMPANIES) 189
TABLE 156 COMPANY FOOTPRINT: BY TYPE (25 COMPANIES) 190
TABLE 157 COMPANY FOOTPRINT: BY SITE OF DELIVERY (25 COMPANIES) 191
TABLE 158 COMPANY FOOTPRINT: BY APPLICATION (25 COMPANIES) 192
13.8 COMPETITIVE SCENARIO 193
13.8.1 PRODUCT LAUNCHES & APPROVALS 193
13.8.2 DEALS 193
TABLE 159 DEALS (2019–2021) 193
13.8.3 EXPANSIONS 194
TABLE 160 EXPANSIONS (2018) 194
14 COMPANY PROFILES 195
14.1 KEY PLAYERS 195
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
14.1.1 PHARMAJET 195
TABLE 161 PHARMAJET: BUSINESS OVERVIEW 195
14.1.2 PORTAL INSTRUMENTS 198
TABLE 162 PORTAL INSTRUMENTS: BUSINESS OVERVIEW 198
14.1.3 MEDICAL INTERNATIONAL TECHNOLOGY INC.(MIT) 200
TABLE 163 MEDICAL INTERNATIONAL TECHNOLOGY INC: BUSINESS OVERVIEW 200
14.1.4 NUGEN MEDICAL DEVICES 202
TABLE 164 NUGEN MEDICAL DEVICES: BUSINESS OVERVIEW 202
14.1.5 CROSSJECT SA 204
TABLE 165 CROSSJECT SA: BUSINESS OVERVIEW 204
14.1.6 BIOJECT MEDICAL TECHNOLOGIES INC. (ACQUIRED BY INOVIO PHARMACEUTICALS, INC.) 206
TABLE 166 BIOJECT MEDICAL TECHNOLOGIES INC.: BUSINESS OVERVIEW 206
14.1.7 ANTARES PHARMA 207
TABLE 167 ANTARES PHARMA: BUSINESS OVERVIEW 207
FIGURE 34 ANTARES PHARMA: COMPANY SNAPSHOT 208
14.1.8 INJEX PHARMA GMBH 210
TABLE 168 INJEX PHARMA GMBH: BUSINESS OVERVIEW 210
14.1.9 NATIONAL MEDICAL PRODUCTS, INC. 211
TABLE 169 NATIONAL MEDICAL PRODUCTS, INC.: BUSINESS OVERVIEW 211
14.1.10 ZEALAND PHARMA A/S. 212
TABLE 170 ZEALAND PHARMA A/S: BUSINESS OVERVIEW 212
14.2 OTHER PLAYERS 213
14.2.1 PENJET CORPORATION 213
TABLE 171 PENJET CORPORATION: BUSINESS OVERVIEW 213
14.2.2 ENESI PHARMA LIMITED 214
14.2.3 INTEGRIMEDICAL LLC 216
TABLE 173 INTEGRIMEDICAL LLC: BUSINESS OVERVIEW 216
14.2.4 AKRA DERMOJET 217
TABLE 174 AKRA DERMOJET: BUSINESS OVERVIEW 217
14.2.5 D'ANTONIO CONSULTANTS INTERNATIONAL, INC. 218
TABLE 175 D'ANTONIO CONSULTANTS INTERNATIONAL, INC: BUSINESS OVERVIEW 218
14.2.6 BASCO INDIA 219
TABLE 176 BASCO INDIA: BUSINESS OVERVIEW 219
14.2.7 MIKA MEDICAL CO. 220
TABLE 177 MIKA MEDICAL CO.: BUSINESS OVERVIEW 220
14.2.8 MADA MEDICAL PRODUCTS, INC. 221
TABLE 178 MADA MEDICAL PRODUCTS, INC.: BUSINESS OVERVIEW 221
14.2.9 VAXXAS 222
TABLE 179 VAXXAS: BUSINESS OVERVIEW 222
14.2.10 GUANGZHOU MEDSINGLONG MEDICAL EQUIPMENT CO., LTD 223
TABLE 180 GUANGZHOU MEDSINGLONG MEDICAL EQUIPMENT CO., LTD: BUSINESS OVERVIEW 223
14.2.11 QUINOVARE 224
TABLE 181 QUINOVARE: BUSINESS OVERVIEW 224
14.2.12 TAPEMARK 225
TABLE 182 TAPEMARK: BUSINESS OVERVIEW 225
14.2.13 THERAJECT 226
TABLE 183 THERAJECT: BUSINESS OVERVIEW 226
14.2.14 ZOSANO PHARMA 227
TABLE 184 ZOSANO PHARMA: BUSINESS OVERVIEW 227
14.2.15 CORIUM 228
TABLE 185 CORIUM: BUSINESS OVERVIEW 228
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
 
15 APPENDIX 229
15.1 DISCUSSION GUIDE 229
15.2 INDUSTRY INSIGHTS 234
15.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 235
15.4 AVAILABLE CUSTOMIZATIONS 237
15.5 RELATED REPORTS 237
15.6 AUTHOR DETAILS 238

Lateral Flow Assay Components Market by Type, Application Type (Clinical Testing (Infectious, Cardiac Marker Test) Veterinary, Food Safety), Technique...

Publisher:        MarketsandMarkets

# of Pages:        224

Rating: 

1 User License $4,950

Publication Date:  April, 2022

Price:       $4,950 / User License




1 INTRODUCTION 33
1.1 OBJECTIVES OF THE STUDY 33
1.2 MARKET DEFINITION 33
1.2.1 CATEGORY-WISE INCLUSIONS AND EXCLUSIONS
IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 33
1.3 MARKET SCOPE 34
1.3.1 MARKETS COVERED 34
FIGURE 1 LATERAL FLOW ASSAY COMPONENTS MARKET SEGMENTATION 34
1.3.2 YEARS CONSIDERED FOR THE STUDY 35
1.4 CURRENCY 35
TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD 35
1.5 STAKEHOLDERS 35
2 RESEARCH METHODOLOGY 36
2.1 RESEARCH APPROACH 36
FIGURE 2 RESEARCH DESIGN 36
2.1.1 SECONDARY DATA 36
2.1.1.1 Key data from secondary sources 37
2.1.2 PRIMARY DATA 38
2.1.2.1 Primary sources 38
2.1.2.2 Key data from primary sources 39
2.1.2.3 Breakdown of primaries 39
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE):
BY COMPANY TYPE, DESIGNATION, AND REGION 39
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY END USER, DESIGNATION, AND REGION 40
2.2 MARKET SIZE ESTIMATION 40
FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS (2021) 41
FIGURE 6 SUPPLY-SIDE ANALYSIS: LATERAL FLOW ASSAY COMPONENTS MARKET (2021) 42
2.3 MARKET BREAKDOWN & DATA TRIANGULATION 44
FIGURE 7 DATA TRIANGULATION METHODOLOGY 45
2.4 KEY INDUSTRY INSIGHTS 46
2.5 LIMITATIONS 46
2.5.1 METHODOLOGY-RELATED LIMITATIONS 46
2.6 RISK ASSESSMENT 47
2.7 ASSUMPTIONS FOR THE STUDY 47
 
3 EXECUTIVE SUMMARY 48
FIGURE 8 LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2022 VS. 2027 (USD MILLION) 48
FIGURE 9 LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2022 VS. 2027 (USD MILLION) 49
FIGURE 10 LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION,
2022 VS. 2027 (USD MILLION) 50
FIGURE 11 LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2022 VS. 2027 (USD MILLION) 51
FIGURE 12 GEOGRAPHICAL SNAPSHOT OF THE LATERAL FLOW ASSAY COMPONENTS MARKET 52
4 PREMIUM INSIGHTS 53
4.1 LATERAL FLOW ASSAY COMPONENTS MARKET OVERVIEW 53
FIGURE 13 RISING NUMBER OF LOCAL MANUFACTURERS FOR COMPONENTS IS DRIVING THE GROWTH OF THE LATERAL FLOW ASSAY COMPONENTS MARKET 53
4.2 REGIONAL MIX: LATERAL FLOW ASSAY COMPONENTS MARKET 54
FIGURE 14 APAC TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD 54
4.3 ASIA PACIFIC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE AND COUNTRY 55
FIGURE 15 MEMBRANES ACCOUNTED FOR THE LARGEST SHARE OF THE ASIA PACIFIC MARKET IN 2021 55
4.4 LATERAL FLOW ASSAY COMPONENTS MARKET: GEOGRAPHICAL GROWTH OPPORTUNITIES 56
4.5 LATERAL FLOW ASSAY COMPONENTS MARKET: DEVELOPED VS. DEVELOPING COUNTRIES 56
5 MARKET OVERVIEW 57
5.1 INTRODUCTION 57
5.2 MARKET DYNAMICS: IMPACT ANALYSIS 57
5.2.1 DRIVERS 58
5.2.1.1 Growing demand for lateral flow assay kits due
to the COVID-19 pandemic 58
5.2.1.2 Growing usage of home-based lateral flow assay devices 58
5.2.1.3 Growing demand for point-of-care testing 58
5.2.1.4 Increasing public-private investments to develop lateral flow assays 59
5.2.2 RESTRAINTS 59
5.2.2.1 Availability of alternative diagnostic technologies 59
5.2.3 OPPORTUNITIES 59
5.2.3.1 Evolving applications of lateral flow assays 59
5.2.4 CHALLENGES 60
5.2.4.1 Requirement of specialized storage and shipping facilities for membranes 60
5.3 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 60
5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES (YC-YCC) IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 60
FIGURE 16 YC–YCC SHIFT IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 61
5.5 AVERAGE SELLING PRICE TREND 61
TABLE 2 AVERAGE SELLING PRICE OF LATERAL FLOW ASSAY COMPONENTS,
BY REGION, 2021 (USD) 61
5.6 ECOSYSTEM MARKET MAP 62
FIGURE 17 ECOSYSTEM: LATERAL FLOW ASSAY COMPONENTS MARKET (2021) 62
5.7 PATENT ANALYSIS 63
5.7.1 PATENT PUBLICATION TRENDS FOR LATERAL FLOW ASSAYS 63
FIGURE 18 GLOBAL PATENT PUBLICATION TRENDS IN THE LATERAL FLOW ASSAY COMPONENTS MARKET, 2016–2021 64
5.7.2 JURISDICTION ANALYSIS: TOP APPLICANTS (COUNTRIES) FOR PATENTS IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 64
FIGURE 19 JURISDICTION ANALYSIS: TOP APPLICANT COUNTRIES FOR LATERAL FLOW ASSAYS COMPONENTS, 2016–2021 64
5.8 VALUE CHAIN ANALYSIS 65
5.9 REGULATORY LANDSCAPE 66
TABLE 3 REGULATORY STANDARDS/APPROVALS REQUIRED FOR LATERAL FLOW IMMUNOASSAY PRODUCTS, BY COUNTRY/REGION 66
5.9.1 NORTH AMERICA 66
5.9.2 EUROPE 67
5.9.3 ASIA PACIFIC 67
5.9.3.1 India 67
5.9.3.2 China 67
5.9.3.3 Japan 68
5.10 TECHNOLOGY ANALYSIS 69
5.10.1 KEY TECHNOLOGY: LATERAL FLOW ASSAYS 69
5.11 KEY CONFERENCES & EVENTS DURING 2021–2023 69
TABLE 4 LATERAL FLOW ASSAY COMPONENTS MARKET: DETAILED LIST OF CONFERENCES & EVENTS 69
5.12 KEY STAKEHOLDERS & BUYING CRITERIA 70
5.12.1 KEY STAKEHOLDERS IN THE BUYING PROCESS 70
FIGURE 20 INFLUENCE OF STAKEHOLDERS IN THE BUYING PROCESS FOR THE TOP 3 APPLICATIONS 70
TABLE 5 INFLUENCE OF STAKEHOLDERS IN THE BUYING PROCESS FOR THE TOP 3 APPLICATIONS 70
5.12.2 BUYING CRITERIA 71
FIGURE 21 KEY BUYING CRITERIA FOR THE TOP 3 APPLICATIONS 71
TABLE 6 KEY BUYING CRITERIA FOR THE TOP 3 APPLICATIONS 71
5.13 PORTER’S FIVE FORCES ANALYSIS 72
TABLE 7 LATERAL FLOW ASSAY COMPONENTS MARKET:
PORTER’S FIVE FORCES ANALYSIS 72
5.13.1 THREAT FROM NEW ENTRANTS 72
5.13.2 THREAT FROM SUBSTITUTES 72
5.13.3 BARGAINING POWER OF BUYERS 73
5.13.4 BARGAINING POWER OF SUPPLIERS 73
5.13.5 INTENSITY OF COMPETITIVE RIVALRY 73
6 LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE 74
6.1 INTRODUCTION 75
TABLE 8 LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 75
6.2 MEMBRANES 75
TABLE 9 LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE,
2020–2027 (USD MILLION) 76
TABLE 10 LATERAL FLOW ASSAY COMPONENTS MARKET FOR MEMBRANES,
BY COUNTRY, 2020–2027 (USD MILLION) 76
6.2.1 NITROCELLULOSE MEMBRANES 77
6.2.1.1 Advantages of nitrocellulose membranes such as high protein-binding affinity and compatibility with a wide range of detection methods to drive market growth 77
TABLE 11 LATERAL FLOW ASSAY COMPONENTS MARKET FOR NITROCELLULOSE MEMBRANES, BY COUNTRY, 2020–2027 (USD MILLION) 77
TABLE 12 LATERAL FLOW ASSAY COMPONENTS MARKET FOR NITROCELLULOSE MEMBRANES (1 X 1 M SHEETS), BY REGION, 2020–2027 (IN THOUSANDS) 78
TABLE 13 LATERAL FLOW ASSAY COMPONENTS MARKET FOR NITROCELLULOSE MEMBRANES (20 MM X 1 M ROLLS), BY REGION, 2020–2027 (IN MILLIONS) 78
6.2.2 OTHER MEMBRANES 78
TABLE 14 LATERAL FLOW ASSAY COMPONENTS MARKET FOR OTHER MEMBRANES,
BY COUNTRY, 2020–2027 (USD MILLION) 79
6.3 PADS 80
TABLE 15 EXAMPLES OF DIFFERENT MATERIALS USED IN MANUFACTURING LATERAL FLOW ASSAY PADS 80
TABLE 16 LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 80
TABLE 17 LATERAL FLOW ASSAY COMPONENTS MARKET FOR PADS, BY COUNTRY, 2020–2027 (USD MILLION) 81
6.3.1 SAMPLE PADS 81
6.3.1.1 Ability to promote even and controlled distribution of samples to drive market growth 81
TABLE 18 LATERAL FLOW ASSAY COMPONENTS MARKET FOR SAMPLE PADS,
BY COUNTRY, 2020–2027 (USD MILLION) 82
6.3.2 CONJUGATE PADS 82
6.3.2.1 Conjugate pads play an important role in controlling the performance of lateral flow immunoassays 82
TABLE 19 LATERAL FLOW ASSAY COMPONENTS MARKET FOR CONJUGATE PADS,
BY COUNTRY, 2020–2027 (USD MILLION) 83
6.3.3 ABSORBENT PADS 84
6.3.3.1 Absorbent pads prevent backflow—a key factor driving market growth 84
TABLE 20 LATERAL FLOW ASSAY COMPONENTS MARKET FOR ABSORBENT PADS,
BY COUNTRY, 2020–2027 (USD MILLION) 84
6.4 OTHER COMPONENTS 84
TABLE 21 OTHER LATERAL FLOW ASSAY COMPONENTS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 85
7 LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION 86
7.1 INTRODUCTION 87
TABLE 22 LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 87
7.2 CLINICAL TESTING 87
TABLE 23 LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 88
TABLE 24 LATERAL FLOW ASSAYS MARKET FOR CLINICAL TESTING APPLICATIONS,
BY COUNTRY, 2020–2027 (USD MILLION) 88
7.2.1 INFECTIOUS DISEASE TESTING 89
7.2.1.1 Rising demand for infectious disease testing in emerging markets to drive market growth 89
TABLE 25 LATERAL FLOW ASSAY COMPONENTS MARKET FOR INFECTIOUS DISEASE TESTING, BY COUNTRY, 2020–2027 (USD MILLION) 89
7.2.2 PREGNANCY & FERTILITY TESTING 90
7.2.2.1 Growing infertility levels due to changing lifestyles—a key factor driving market growth 90
TABLE 26 LATERAL FLOW ASSAY COMPONENTS MARKET FOR PREGNANCY & FERTILITY TESTING, BY COUNTRY, 2020–2027 (USD MILLION) 90
7.2.3 CARDIAC MARKER TESTING 91
7.2.3.1 Rising prevalence of cardiovascular diseases and growing government support to drive growth in this market segment 91
TABLE 27 LATERAL FLOW ASSAY COMPONENTS MARKET FOR CARDIAC MARKER TESTING, BY COUNTRY, 2020–2027 (USD MILLION) 92
7.2.4 CHOLESTEROL TESTING/LIPID PROFILING 92
7.2.4.1 Growing prevalence of obesity and CVD—
a key factor driving market growth 92
TABLE 28 LATERAL FLOW ASSAY COMPONENTS MARKET FOR CHOLESTEROL TESTING/LIPID PROFILING, BY COUNTRY, 2020–2027 (USD MILLION) 93
7.2.5 DRUGS-OF-ABUSE TESTING 93
7.2.5.1 Technological advancements and a growing focus on workplace
drug testing are driving market growth 93
TABLE 29 LATERAL FLOW ASSAY COMPONENTS MARKET FOR DRUGS-OF-ABUSE TESTING, BY COUNTRY, 2020–2027 (USD MILLION) 94
7.2.6 OTHER CLINICAL TESTING APPLICATIONS 94
TABLE 30 LATERAL FLOW ASSAY COMPONENTS MARKET FOR OTHER CLINICAL TESTING APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 95
7.3 VETERINARY DIAGNOSTICS 95
7.3.1 INFECTIOUS DISEASE OUTBREAKS (PARTICULARLY IN LARGE LIVESTOCK ANIMALS) TO DRIVE MARKET GROWTH 95
TABLE 31 LATERAL FLOW ASSAY COMPONENTS MARKET FOR VETERINARY DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 96
7.4 FOOD SAFETY & ENVIRONMENTAL TESTING 96
7.4.1 HIGH SENSITIVITY AND EASE OF USE ARE KEY FACTORS DRIVING THE DEMAND FOR LATERAL FLOW ASSAYS FOR FOOD SAFETY TESTING 96
TABLE 32 LATERAL FLOW ASSAY COMPONENTS MARKET FOR FOOD SAFETY & ENVIRONMENTAL TESTING APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 97
7.5 DRUG DEVELOPMENT & QUALITY TESTING 97
7.5.1 INCREASING FOCUS ON PRODUCT SAFETY AND QUALITY ASSURANCE TO DRIVE MARKET GROWTH IN THE COMING YEARS 97
TABLE 33 LATERAL FLOW ASSAY COMPONENTS MARKET FOR DRUG DEVELOPMENT & QUALITY TESTING APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 98
8 LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE 99
8.1 INTRODUCTION 100
TABLE 34 LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION) 100
8.2 SANDWICH ASSAYS 100
8.2.1 SANDWICH ASSAYS PROVIDE HIGHER LEVELS OF ASSAY SENSITIVITY AND SPECIFICITY THAN OTHER ASSAY TECHNIQUES—A KEY FACTOR DRIVING GROWTH IN THIS MARKET SEGMENT 100
TABLE 35 LATERAL FLOW ASSAY COMPONENTS MARKET FOR SANDWICH ASSAYS,
BY COUNTRY, 2020–2027 (USD MILLION) 101
8.3 COMPETITIVE ASSAYS 101
8.3.1 REDUCED SELECTIVITY AND SENSITIVITY OF COMPETITIVE ASSAYS IN RELATION TO SANDWICH ASSAYS COULD HAMPER MARKET GROWTH 101
TABLE 36 LATERAL FLOW ASSAY COMPONENTS MARKET FOR COMPETITIVE ASSAYS,
BY COUNTRY, 2020–2027 (USD MILLION) 102
8.4 MULTIPLEX DETECTION ASSAYS 102
8.4.1 INCREASING ADOPTION OF MULTI-ANALYTE ASSAYS AMONG CLINICIANS TO DRIVE MARKET GROWTH 102
TABLE 37 LATERAL FLOW ASSAY COMPONENTS MARKET FOR MULTIPLEX DETECTION ASSAYS, BY COUNTRY, 2020–2027 (USD MILLION) 103
9 LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER 104
9.1 INTRODUCTION 105
TABLE 38 LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 105
9.2 MEDICAL DEVICE MANUFACTURING COMPANIES 105
9.2.1 INCREASING USE OF POC TESTS IS DRIVING THE ADOPTION OF LATERAL FLOW ASSAY COMPONENTS AMONG MEDICAL DEVICE MANUFACTURING COMPANIES 105
TABLE 39 LATERAL FLOW ASSAY COMPONENTS MARKET FOR MEDICAL DEVICE MANUFACTURING COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION) 106
9.3 MEDICAL DEVICE CONTRACT MANUFACTURING COMPANIES 106
9.3.1 GROWING INCLINATION TOWARD FAST AND EARLY DIAGNOSIS, ESPECIALLY IN RELATION TO THE CURRENT COVID-19 SCENARIO, WILL DRIVE MARKET GROWTH 106
TABLE 40 LATERAL FLOW ASSAY COMPONENTS MARKET FOR MEDICAL DEVICE CONTRACT MANUFACTURING COMPANIES, BY COUNTRY,
2020–2027 (USD MILLION) 107
 
10 LATERAL FLOW ASSAY COMPONENTS MARKET, BY REGION 108
10.1 INTRODUCTION 109
FIGURE 22 CHINA TO REGISTER THE HIGHEST GROWTH IN THE LATERAL FLOW ASSAY COMPONENTS MARKET DURING THE FORECAST PERIOD 109
TABLE 41 LATERAL FLOW ASSAY COMPONENTS MARKET, BY REGION,
2020–2027 (USD MILLION) 110
10.2 NORTH AMERICA 110
TABLE 42 NORTH AMERICA: MACROECONOMIC INDICATORS 110
FIGURE 23 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET SNAPSHOT 111
TABLE 43 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 112
TABLE 44 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 112
TABLE 45 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 112
TABLE 46 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY PAD TYPE, 2020–2027 (USD MILLION) 113
TABLE 47 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY APPLICATION, 2020–2027 (USD MILLION) 113
TABLE 48 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 114
TABLE 49 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY TECHNIQUE, 2020–2027 (USD MILLION) 114
TABLE 50 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY END USER, 2020–2027 (USD MILLION) 115
10.2.1 US 115
10.2.1.1 Increasing R&D investments and venture capital funding from both large and small firms towards the development of lateral flow assay diagnostics to drive market growth in the US 115
TABLE 51 US: MACROECONOMIC INDICATORS 116
TABLE 52 US: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 116
TABLE 53 US: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 116
TABLE 54 US: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 117
TABLE 55 US: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 117
TABLE 56 US: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 118
TABLE 57 US: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION) 118
TABLE 58 US: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 119
10.2.2 CANADA 119
10.2.2.1 Lateral flow assay components market in Canada is estimated to grow at a relatively lower rate than the US 119
TABLE 59 CANADA: MACROECONOMIC INDICATORS 119
TABLE 60 CANADA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 120
TABLE 61 CANADA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 120
TABLE 62 CANADA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE, 2020–2027 (USD MILLION) 120
TABLE 63 CANADA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 121
TABLE 64 CANADA: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 121
TABLE 65 CANADA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 122
TABLE 66 CANADA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 122
10.3 EUROPE 122
TABLE 67 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 123
TABLE 68 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 123
TABLE 69 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 123
TABLE 70 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE, 2020–2027 (USD MILLION) 124
TABLE 71 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 124
TABLE 72 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 125
TABLE 73 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 125
TABLE 74 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 126
10.3.1 GERMANY 126
10.3.1.1 Growing demand for POC testing to drive the lateral flow assay components market in Germany 126
TABLE 75 GERMANY: MACROECONOMIC INDICATORS 126
TABLE 76 GERMANY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 127
TABLE 77 GERMANY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 127
TABLE 78 GERMANY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE, 2020–2027 (USD MILLION) 127
TABLE 79 GERMANY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 128
TABLE 80 GERMANY: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 128
TABLE 81 GERMANY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 129
TABLE 82 GERMANY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 129
10.3.2 FRANCE 129
10.3.2.1 High prevalence of age-related chronic diseases and infectious diseases to drive market growth in France 129
TABLE 83 FRANCE: MACROECONOMIC INDICATORS 130
TABLE 84 FRANCE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 130
TABLE 85 FRANCE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 130
TABLE 86 FRANCE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE, 2020–2027 (USD MILLION) 131
TABLE 87 FRANCE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 131
TABLE 88 FRANCE: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 132
TABLE 89 FRANCE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 132
TABLE 90 FRANCE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 133
10.3.3 UK 133
10.3.3.1 Severe impact of the second wave of COVID-19 in the first half of 2021 resulted in higher adoption of rapid COVID tests in the UK 133
TABLE 91 UK: MACROECONOMIC INDICATORS 134
TABLE 92 UK: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 134
TABLE 93 UK: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 134
TABLE 94 UK: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 135
TABLE 95 UK: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 135
TABLE 96 UK: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 136
TABLE 97 UK: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION) 136
TABLE 98 UK: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 137
10.3.4 ITALY 137
10.3.4.1 Growing initiatives towards decentralization of medical services in Italy are contributing to the market growth in the country 137
TABLE 99 ITALY: MACROECONOMIC INDICATORS 137
TABLE 100 ITALY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 138
TABLE 101 ITALY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 138
TABLE 102 ITALY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 138
TABLE 103 ITALY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 139
TABLE 104 ITALY: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 139
TABLE 105 ITALY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION) 140
TABLE 106 ITALY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 140
10.3.5 SPAIN 140
10.3.5.1 Increasing focus of international organizations and domestic players on the development of POC products in the country to drive market growth 140
TABLE 107 SPAIN: MACROECONOMIC INDICATORS 141
TABLE 108 SPAIN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 141
TABLE 109 SPAIN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 142
TABLE 110 SPAIN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 142
TABLE 111 SPAIN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 142
TABLE 112 SPAIN: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 143
TABLE 113 SPAIN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 143
TABLE 114 SPAIN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 144
10.3.6 REST OF EUROPE 144
TABLE 115 ROE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 144
TABLE 116 ROE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 145
TABLE 117 ROE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 145
TABLE 118 ROE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 145
TABLE 119 ROE: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 146
TABLE 120 ROE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION) 146
TABLE 121 ROE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 147
10.4 ASIA PACIFIC 147
FIGURE 24 ASIA PACIFIC: LATERAL FLOW ASSAY COMPONENTS MARKET SNAPSHOT 148
TABLE 122 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 149
TABLE 123 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 149
TABLE 124 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 149
TABLE 125 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 150
TABLE 126 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 150
TABLE 127 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 151
TABLE 128 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION) 151
TABLE 129 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 152
10.4.1 CHINA 152
10.4.1.1 Higher exports of lateral flow assay components during the COVID-19 pandemic to drive market growth in the country 152
TABLE 130 CHINA: MACROECONOMIC INDICATORS 153
TABLE 131 CHINA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 153
TABLE 132 CHINA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 153
TABLE 133 CHINA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 154
TABLE 134 CHINA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 154
TABLE 135 CHINA: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 155
TABLE 136 CHINA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 155
TABLE 137 CHINA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 156
10.4.2 JAPAN 156
10.4.2.1 Increasing prevalence of age-related illnesses driving the growth of the lateral flow assay components market in Japan 156
TABLE 138 JAPAN: MACROECONOMIC INDICATORS 157
TABLE 139 JAPAN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 157
TABLE 140 JAPAN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 157
TABLE 141 JAPAN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 158
TABLE 142 JAPAN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 158
TABLE 143 JAPAN: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 159
TABLE 144 JAPAN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 159
TABLE 145 JAPAN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 160
10.4.3 INDIA 160
10.4.3.1 Increasing number of local manufacturers, growing healthcare concerns, and rising income levels to propel the growth of this market 160
TABLE 146 INDIA: MACROECONOMIC INDICATORS 160
TABLE 147 INDIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 161
TABLE 148 INDIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 161
TABLE 149 INDIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 161
TABLE 150 INDIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 162
TABLE 151 INDIA: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 162
TABLE 152 INDIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION) 163
TABLE 153 INDIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 163
10.4.4 AUSTRALIA 164
10.4.4.1 Increasing prevalence of infectious diseases, especially influenza, to drive the growth of the lateral flow assay components market in Australia 164
TABLE 154 AUSTRALIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 164
TABLE 155 AUSTRALIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 164
TABLE 156 AUSTRALIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE, 2020–2027 (USD MILLION) 165
TABLE 157 AUSTRALIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 165
TABLE 158 AUSTRALIA: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 166
TABLE 159 AUSTRALIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 166
TABLE 160 AUSTRALIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 167
10.4.5 REST OF ASIA PACIFIC 167
TABLE 161 ROAPAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 167
TABLE 162 ROAPAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 168
TABLE 163 ROAPAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE, 2020–2027 (USD MILLION) 168
TABLE 164 ROAPAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 168
TABLE 165 ROAPAC: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 169
TABLE 166 ROAPAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 169
TABLE 167 ROAPAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 170
 
10.5 LATIN AMERICA 170
10.5.1 HIGH DEMAND FOR HIV POC DEVICES IN THE REGION TO SUPPORT THE GROWTH OF THE MARKET 170
TABLE 168 LATIN AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 171
TABLE 169 LATIN AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 171
TABLE 170 LATIN AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD
TYPE, 2020–2027 (USD MILLION) 171
TABLE 171 LATIN AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY APPLICATION, 2020–2027 (USD MILLION) 172
TABLE 172 LATIN AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 172
TABLE 173 LATIN AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY TECHNIQUE, 2020–2027 (USD MILLION) 173
TABLE 174 LATIN AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY END USER, 2020–2027 (USD MILLION) 173
10.6 MIDDLE EAST & AFRICA 173
10.6.1 SIGNIFICANT SUPPORT FROM GOVERNMENTS AND GLOBAL FIRMS TOWARDS EXPANDING HEALTHCARE SERVICES DRIVES THE ADOPTION OF LATERAL FLOW ASSAYS 173
TABLE 175 MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS 174
TABLE 176 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY TYPE, 2020–2027 (USD MILLION) 174
TABLE 177 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 175
TABLE 178 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY PAD TYPE, 2020–2027 (USD MILLION) 175
TABLE 179 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY APPLICATION, 2020–2027 (USD MILLION) 175
TABLE 180 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 176
TABLE 181 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY TECHNIQUE, 2020–2027 (USD MILLION) 176
TABLE 182 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY END USER, 2020–2027 (USD MILLION) 177
11 COMPETITIVE LANDSCAPE 178
11.1 OVERVIEW 178
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 178
FIGURE 25 OVERVIEW OF STRATEGIES ADOPTED BY MAJOR PLAYERS IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 179
11.3 REVENUE SHARE ANALYSIS FOR KEY PLAYERS IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 179
FIGURE 26 REVENUE SHARE ANALYSIS FOR THE KEY PLAYERS
IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 180
11.4 MARKET SHARE ANALYSIS 180
FIGURE 27 LATERAL FLOW ASSAY COMPONENTS MARKET SHARE ANALYSIS, BY KEY PLAYER (2021) 181
TABLE 183 LATERAL FLOW ASSAY COMPONENTS MARKET: DEGREE OF COMPETITION 182
11.5 R&D ASSESSMENT OF KEY PLAYERS 183
FIGURE 28 R&D EXPENDITURE: MAJOR PLAYERS IN THE LATERAL FLOW ASSAY COMPONENTS MARKET, 2018 VS. 2020 183
11.6 GEOGRAPHIC REVENUE ASSESSMENT OF KEY PLAYERS 183
FIGURE 29 GEOGRAPHIC REVENUE ASSESSMENT: LATERAL FLOW ASSAY COMPONENTS MARKET (2021) 184
11.7 COMPANY EVALUATION QUADRANT 184
11.7.1 STARS 184
11.7.2 PERVASIVE PLAYERS 184
11.7.3 EMERGING LEADERS 185
11.7.4 PARTICIPANTS 185
FIGURE 30 LATERAL FLOW ASSAY COMPONENTS MARKET: COMPANY EVALUATION MATRIX, 2021 185
11.8 COMPETITIVE BENCHMARKING 186
11.8.1 OVERALL COMPANY FOOTPRINT 186
TABLE 184 OVERALL COMPANY FOOTPRINT (17 COMPANIES) 186
TABLE 185 COMPANY FOOTPRINT: BY TYPE (17 COMPANIES) 187
TABLE 186 COMPANY FOOTPRINT: BY REGION (17 COMPANIES) 188
11.9 COMPETITIVE SCENARIO 188
11.9.1 DEALS 189
TABLE 187 DEALS, JANUARY 2019–FEBRUARY 2022 189
11.9.2 OTHER DEVELOPMENTS 189
TABLE 188 OTHER DEVELOPMENTS, JANUARY 2019–FEBRUARY 2022 189
12 COMPANY PROFILES 190
12.1 KEY PLAYERS 190
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
12.1.1 DANAHER CORPORATION (PALL CORPORATION AND CYTIVA LIFE SCIENCE) 190
TABLE 189 DANAHER CORPORATION: BUSINESS OVERVIEW 190
FIGURE 31 DANAHER CORPORATION: COMPANY SNAPSHOT (2020) 191
12.1.2 SARTORIUS STEDIM BIOTECH 195
TABLE 190 SARTORIUS STEDIM BIOTECH: BUSINESS OVERVIEW 195
12.1.3 MERCK KGAA 199
TABLE 191 MERCK KGAA: BUSINESS OVERVIEW 199
FIGURE 33 MERCK KGAA: COMPANY SNAPSHOT (2020) 200
12.1.4 AHLSTROM-MUNKSJÖ 204
TABLE 192 AHLSTROM-MUNKSJÖ: BUSINESS OVERVIEW 204
FIGURE 34 AHLSTROM-MUNKSJÖ: COMPANY SNAPSHOT (2020) 205
12.1.5 ADVANCED MICRODEVICES PVT. LTD. 208
TABLE 193 ADVANCED MICRODEVICES PVT. LTD.: BUSINESS OVERVIEW 208
12.1.6 DCN DIAGNOSTICS 210
TABLE 194 DCN DIAGNOSTICS: BUSINESS OVERVIEW 210
12.2 OTHER PLAYERS 211
12.2.1 FORTIS LIFE SCIENCES 211
TABLE 195 FORTIS LIFE SCIENCES: BUSINESS OVERVIEW 211
12.2.2 HANGZHOU COBETTER FILTRATION EQUIPMENT CO. LTD 212
TABLE 196 HANGZHOU COBETTER FILTRATION EQUIPMENT CO. LTD.:
BUSINESS OVERVIEW 212
12.2.3 AXIVA SICHEM BIOTECH 214
TABLE 197 AXIVA SICHEM BIOTECH: BUSINESS OVERVIEW 214
12.2.4 NUPORE FILTRATION SYSTEM 216
TABLE 198 NUPORE FILTRATION SYSTEM: BUSINESS OVERVIEW 216
12.2.5 BALLYA BIO 217
TABLE 199 BALLYA BIO: BUSINESS OVERVIEW 217
12.2.6 RUNBIO BIOTECH CO. LTD. 219
TABLE 200 RUNBIO BIOTECH CO. LTD.: BUSINESS OVERVIEW 219
12.2.7 NEENAH GESSNER 220
TABLE 201 NEENAH GESSNER: BUSINESS OVERVIEW 220
12.2.8 MAXIM BIOMEDICAL 221
TABLE 202 MAXIM BIOMEDICAL: BUSINESS OVERVIEW 221
12.2.9 CYTODIAGNOSTICS 222
TABLE 203 CYTODIAGNOSTICS: BUSINESS OVERVIEW 222
12.2.10 SENOVA GMBH 223
TABLE 204 SENOVA GMBH: BUSINESS OVERVIEW 223
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
13 APPENDIX 224
13.1 DISCUSSION GUIDE 224
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 229
13.3 AVAILABLE CUSTOMIZATIONS 231
13.4 RELATED REPORTS 231
13.5 AUTHOR DETAILS 232

US Healthcare Environmental Services Market by Type (Janitorial/Core-Cleaning, Infection Control & Prevention, Front-of-house cleaning & Brand Experie...

Publisher:        MarketsandMarkets

# of Pages:        126

Rating: 

1 User License $4,950

Publication Date:  March, 2022

Price:       $4,950 / User License




1 INTRODUCTION 15
1.1 OBJECTIVES OF THE STUDY 15
1.2 MARKET DEFINITION & SCOPE 15
1.2.1 INCLUSIONS & EXCLUSIONS OF THE STUDY 16
1.2.2 MARKET SEGMENTATION 16
FIGURE 1 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET SEGMENTATION 16
1.2.3 YEARS CONSIDERED FOR THE STUDY 17
1.3 CURRENCY 17
TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD 17
1.4 STAKEHOLDERS 18
2 RESEARCH METHODOLOGY 19
2.1 RESEARCH APPROACH 19
FIGURE 2 RESEARCH DESIGN 19
2.1.1 SECONDARY RESEARCH 20
2.1.1.1 Key data from secondary sources 21
2.1.2 PRIMARY RESEARCH 21
FIGURE 3 PRIMARY SOURCES 22
2.1.2.1 Key data from primary sources 23
2.1.2.2 Insights from primary experts 23
2.1.2.3 Breakdown of primary interviews 24
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE (SUPPLY & DEMAND SIDE) AND DESIGNATION 24
2.2 MARKET SIZE ESTIMATION 25
FIGURE 5 MARKET SIZE APPROACH – REVENUE SHARE ANALYSIS 25
FIGURE 6 CAGR PROJECTIONS FROM THE ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 26
FIGURE 7 DEMAND-SIDE APPROACH 28
2.3 DATA TRIANGULATION 29
FIGURE 8 DATA TRIANGULATION METHODOLOGY 29
2.4 MARKET RANKING ANALYSIS 30
2.5 ASSUMPTIONS FOR THE STUDY 30
2.6 LIMITATIONS 31
2.6.1 METHODOLOGY-RELATED LIMITATIONS 31
2.6.2 SCOPE-RELATED LIMITATIONS 31
2.7 RISK ASSESSMENT 31
TABLE 2 RISK ASSESSMENT: US HEALTHCARE ENVIRONMENTAL SERVICES MARKET 31
 
3 EXECUTIVE SUMMARY 32
FIGURE 9 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET, BY TYPE,
2021 VS. 2026 (USD MILLION) 32
FIGURE 10 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET,
BY FACILITY TYPE, 2021 VS. 2026 (USD MILLION) 33
4 PREMIUM INSIGHTS 34
4.1 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET OVERVIEW 34
FIGURE 11 STRINGENT REGULATORY GUIDELINES ON INFECTION CONTROL & PREVENTION METHODS IS A KEY FACTOR DRIVING THE MARKET GROWTH 34
4.2 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET, BY TYPE AND FACILITY TYPE 35
FIGURE 12 JANITORIAL/CORE-CLEANING SERVICES ACCOUNTED FOR THE LARGEST SHARE OF THE US HEALTHCARE ENVIRONMENTAL SERVICES
MARKET IN 2020 35
4.3 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET, BY FACILITY TYPE (2021–2026) 36
FIGURE 13 ACUTE CARE FACILITIES TO DOMINATE THE US HEALTHCARE ENVIRONMENTAL SERVICES MARKET DURING THE FORECAST PERIOD 36
5 MARKET OVERVIEW 37
5.1 INTRODUCTION 37
5.2 MARKET DYNAMICS 37
TABLE 3 MARKET DYNAMICS: HEALTHCARE ENVIRONMENTAL SERVICES MARKET 37
5.2.1 MARKET DRIVERS 38
5.2.1.1 Increasing prevalence of Hospital-acquired infections (HAIs) 38
5.2.1.2 Rising number of hospital admissions and surgeries 39
TABLE 4 US: PERCENTAGE INCREASE IN THE NUMBER OF SURGERIES PERFORMED 39
FIGURE 14 TOTAL ADMISSIONS IN ALL US HOSPITALS 40
FIGURE 15 TOTAL NUMBER OF HOSPITALS IN THE US 40
5.2.1.3 Shortage of in-house expertise and the rising need to reduce healthcare costs 41
5.2.1.4 Increasing outsourcing of cleaning services 41
5.2.2 MARKET RESTRAINTS 41
5.2.2.1 Healthcare facilities with an in-house EVS department 41
5.2.3 MARKET OPPORTUNITIES 42
5.2.3.1 Sustained acquisitions among strategic & financial buyers 42
TABLE 5 COMPANY ACQUISITIONS 42
5.2.4 MARKET CHALLENGES 42
5.2.4.1 Noncompliance with cleaning standards by EVS providers 42
5.3 INDUSTRY TRENDS 43
5.3.1 EMERGENCE OF NEW SURFACE DISINFECTANTS &
GREEN CLEANING PRODUCTS 43
5.3.2 DISINFECTION ROBOTS 44
5.3.3 MONITORING TOOLS FOR CLEANING QUALITY ASSESSMENT 44
5.4 TECHNOLOGY ANALYSIS 45
TABLE 6 TECHNOLOGY INNOVATION IN THE HEALTHCARE ENVIRONMENTAL
SERVICES MARKET 45
5.5 PATENT ANALYSIS 45
5.5.1 PATENT PUBLICATION TRENDS FOR HEALTHCARE ENVIRONMENTAL SERVICES 46
FIGURE 16 PATENT PUBLICATION TRENDS (JANUARY 2011–DECEMBER 2021) 46
5.5.2 JURISDICTION AND TOP APPLICANT ANALYSIS 47
FIGURE 17 TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTIONS) FOR HEALTHCARE ENVIRONMENTAL SERVICES PATENTS (JANUARY 2011–JANUARY 2022) 47
FIGURE 18 TOP APPLICANT COUNTRIES/REGIONS FOR HEALTHCARE ENVIRONMENTAL SERVICES PATENTS (JANUARY 2011–JANUARY 2022) 48
TABLE 7 LIST OF PATENTS/PATENT APPLICATIONS IN THE HEALTHCARE ENVIRONMENTAL SERVICES MARKET, 2020–2021 48
5.6 IMPACT OF COVID-19 ON THE HEALTHCARE ENVIRONMENTAL SERVICES MARKET 50
6 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET, BY TYPE 51
6.1 INTRODUCTION 52
TABLE 8 US: HEALTHCARE ENVIRONMENTAL SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 52
6.2 JANITORIAL SERVICES/CORE-CLEANING SERVICES 52
6.2.1 MANDATORY REGULAR CLEANING AND DISINFECTION OF HEALTHCARE FACILITIES TO DRIVE THE MARKET GROWTH 52
6.3 INFECTION PREVENTION & CONTROL SERVICES 53
TABLE 9 US: INFECTION PREVENTION & CONTROL SERVICE MARKET, BY TYPE,
2019–2026 (USD MILLION) 53
6.3.1 SPECIALIZED CLEANING SERVICES 53
6.3.1.1 Rising adoption of specialized services to reduce HAIs to drive the market growth 53
6.3.2 INFECTION PREVENTION & CONTROL CONSULTATION SERVICES 53
6.3.2.1 The provision of customized environmental services specific
to a healthcare facility ensures market demand 53
6.4 ENHANCED CLEANING TECHNOLOGY 54
6.4.1 RISING DEMAND FOR ADVANCED CLEANING SOLUTIONS TO DRIVE THE SEGMENT GROWTH 54
TABLE 10 EXAMPLES OF COMPANIES PROVIDING TECHNOLOGY & INNOVATION IN HEALTHCARE EVS 54
6.5 FRONT-OF-HOUSE CLEANING AND BRAND EXPERIENCE 56
6.5.1 RISING AWARENESS TOWARDS A CLEAN AND SAFE ENVIRONMENT DURING PANDEMICS TO SUSTAIN THE MARKET GROWTH 56
6.6 OTHER SERVICES 56
 
7 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET, BY FACILITY TYPE 57
7.1 INTRODUCTION 58
FIGURE 19 STATES WITH THE HIGHEST NUMBER OF COVID-19 ADMISSIONS
(FEBRUARY 2022) 58
TABLE 11 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET, BY FACILITY TYPE, 2019–2026 (USD MILLION) 59
7.2 ACUTE-CARE FACILITIES 59
TABLE 12 US: HEALTHCARE ENVIRONMENTAL SERVICES FOR ACUTE-CARE SETTINGS, BY TYPE 2019–2026 (USD MILLION) 59
7.2.1 ACUTE HOSPITALS 60
7.2.1.1 Increasing hospital admissions due to COVID-19 and the rising prevalence of HAIs propel the market growth 60
FIGURE 20 NUMBER OF HAIS REPORTED BY GENERAL ACUTE CARE HOSPITALS
IN THE US (2020) 60
FIGURE 21 HAIS REPORTED BY GENERAL ACUTE CARE HOSPITALS IN THE US (2020) 61
FIGURE 22 HAIS REPORTED BY CRITICAL ACCESS HOSPITALS (CAHS) IN THE US (2018) 61
7.2.2 MILITARY TREATMENT FACILITY 61
7.2.2.1 The increasing number of military ambulatory health services & funding to drive the market growth 61
FIGURE 23 MILITARY HEALTH SYSTEMS FACILITIES IN THE US (2021) 62
7.2.3 CHILDREN’S HOSPITALS 62
7.2.3.1 Rising cases of COVID-19 and infection-related mortality rates among children drive the market growth 62
7.2.4 AMBULATORY SURGERY CENTERS (ASCS) 63
7.2.4.1 ASCs save time and reduce the risk of HAIS; key factor driving the market growth 63
FIGURE 24 US SURGERY CASES BY SETTING: ASC VS. HOPD (2005-2020) 64
7.2.5 ACADEMIC MEDICAL CENTERS (AMCS) 64
7.2.5.1 Healthcare capacity expansion during COVID-19 drives the adoption of healthcare environmental services in AMCs 64
7.3 POST-ACUTE CARE FACILITIES 64
TABLE 13 US: HEALTHCARE ENVIRONMENTAL SERVICES FOR POST-ACUTE CARE SETTINGS, BY TYPE 2019–2026 (USD MILLION) 65
7.3.1 LONG-TERM ACUTE HOSPITALS (LTACH) 65
7.3.1.1 Increasing risk of infection due to prolonged hospital stays to drive the market growth 65
7.3.2 SKILLED NURSING FACILITIES (SNF) 66
7.3.2.1 Increasing admissions of elderly people in skilled nursing facilities to drive the market growth 66
7.3.3 OTHER POST-ACUTE CARE FACILITIES 66
7.4 NON-ACUTE CARE FACILITIES 67
TABLE 14 US: ENVIRONMENTAL SERVICES MARKET FOR NON-ACUTE CARE SETTINGS, BY TYPE, 2019–2026 (USD MILLION) 67
7.4.1 PHYSICIAN’S OFFICES AND CLINICS 67
7.4.1.1 High patient traffic leads to continuous cleaning & maintenance to drive the market growth 67
7.4.2 OTHER NON-ACUTE CARE FACILITIES 68
FIGURE 25 DISTRIBUTION OF INDUSTRY MEDICAL AND HEALTH R&D INVESTMENTS,
BY SEGMENT (2020) 68
8 COMPETITIVE LANDSCAPE 70
8.1 OVERVIEW 70
8.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 70
8.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN THE HEALTHCARE ENVIRONMENTAL SERVICES MARKET 71
8.3 REVENUE SHARE ANALYSIS OF THE TOP MARKET PLAYERS 72
8.4 MARKET RANKING ANALYSIS 73
FIGURE 27 US HEALTHCARE ENVIRONMENTAL SERVICE MARKET RANKING,
BY KEY PLAYER, 2020 73
8.5 COMPETITIVE BENCHMARKING 75
TABLE 15 FOOTPRINT OF COMPANIES IN THE HEALTHCARE ENVIRONMENTAL
SERVICES MARKET 75
TABLE 16 SERVICE FOOTPRINT OF COMPANIES 76
TABLE 17 END-USER FOOTPRINT OF COMPANIES 77
8.6 COMPETITIVE LEADERSHIP MAPPING 77
8.6.1 STARS 78
8.6.2 EMERGING LEADERS 78
8.6.3 PERVASIVE PLAYERS 78
8.6.4 PARTICIPANTS 78
FIGURE 28 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET:
COMPETITIVE LEADERSHIP MAPPING (2021) 79
8.7 COMPETITIVE SCENARIO 80
8.7.1 SERVICE APPROVALS/ENHANCEMENTS 80
8.7.2 DEALS 81
TABLE 19 DEALS, 2018–2022 81
8.7.3 OTHER DEVELOPMENTS 82
9 COMPANY PROFILES 83
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
9.1 SODEXO GLOBAL 83
TABLE 21 SODEXO GLOBAL: BUSINESS OVERVIEW 83
FIGURE 29 SODEXO GLOBAL: COMPANY SNAPSHOT (2021) 84
9.2 COMPASS GROUP (CROTHALL HEALTHCARE (US)) 87
TABLE 22 COMPASS GROUP: BUSINESS OVERVIEW 87
FIGURE 30 COMPASS GROUP: COMPANY SNAPSHOT (2021) 88
 
9.3 ARAMARK CORPORATION 90
TABLE 23 ARAMARK CORPORATION: BUSINESS OVERVIEW 90
FIGURE 31 ARAMARK CORPORATION: COMPANY SNAPSHOT (2021) 91
9.4 HOSPITAL HOUSEKEEPING SYSTEMS (HHS) (US) 94
TABLE 24 HOSPITAL HOUSEKEEPING SYSTEMS (HHS): BUSINESS OVERVIEW 94
9.5 HEALTHCARE SERVICES GROUP, INC. 97
TABLE 25 HEALTHCARE SERVICES GROUP, INC.: BUSINESS OVERVIEW 97
FIGURE 32 HEALTHCARE SERVICES GROUP: COMPANY SNAPSHOT (2020) 98
9.6 ABM INDUSTRIES INCORPORATED 100
TABLE 26 ABM INDUSTRIES INCORPORATED: BUSINESS OVERVIEW 100
FIGURE 33 ABM INDUSTRIES INCORPORATED: COMPANY SNAPSHOT (2020) 101
9.7 OCTOCLEAN 103
TABLE 27 OCTOCLEAN: BUSINESS OVERVIEW 103
9.8 SERVICEMASTER CLEAN (SERVICEMASTER TBS) 105
TABLE 28 SERVICEMASTER CLEAN.: BUSINESS OVERVIEW 105
9.9 CORVUS JANITORIAL SYSTEMS 107
TABLE 29 CORVUS JANITORIAL SYSTEMS: BUSINESS OVERVIEW 107
9.10 BRAVO! BUILDING SERVICES 109
TABLE 30 BRAVO! BUILDING SERVICES: BUSINESS OVERVIEW 109
9.11 POWERLINK ENVIRONMENTAL SERVICES, LLC 111
TABLE 31 POWERLINK ENVIRONMENTAL SERVICES, LLC: BUSINESS OVERVIEW 111
9.12 JANI-KING INTERNATIONAL, INC. 112
TABLE 32 JANI- KING INTERNATIONAL, INC: BUSINESS OVERVIEW 112
9.13 AVI FOOD SYSTEMS(US) 114
TABLE 33 AVI FOOD SYTEMS, INC.: BUSINESS OVERVIEW 114
9.14 SERVICON 115
TABLE 34 SERVICON: BUSINESS OVERVIEW 115
9.15 XANITOS, INC. 117
TABLE 35 XANITOS, INC.: BUSINESS OVERVIEW 117
9.16 STATHAKIS 119
TABLE 36 STATHAKIS: BUSINESS OVERVIEW 119
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
10 APPENDIX 120
10.1 INSIGHTS FROM INDUSTRY EXPERTS 120
10.2 DISCUSSION GUIDE 121
10.3 KNOWLEDGESTORE: MARKETSANDMARKETS SUBSCRIPTION PORTAL 124
10.4 AVAILABLE CUSTOMIZATIONS 126
10.5 RELATED REPORTS 126
10.6 AUTHOR DETAILS 127